Crispr Therapeutics AG
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $50.25
- Today's High:
- $51.6036
- Open Price:
- $51.27
- 52W Low:
- $38.94
- 52W High:
- $86.95
- Prev. Close:
- $51.07
- Volume:
- 510515
Company Statistics
- Market Cap.:
- $5.01 billion
- Book Value:
- 23.52
- Revenue TTM:
- $100.26 million
- Operating Margin TTM:
- -560.23%
- Gross Profit TTM:
- $-570697000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -14.48%
- Return on Equity TTM:
- -25.56%
Company Profile
Crispr Therapeutics AG had its IPO on 2016-10-19 under the ticker symbol CRSP.
The company operates in the Healthcare sector and Biotechnology industry. Crispr Therapeutics AG has a staff strength of 458 employees.
Stock update
Shares of Crispr Therapeutics AG opened at $51.27 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $50.25 - $51.6, and closed at $50.37.
This is a -1.37% slip from the previous day's closing price.
A total volume of 510,515 shares were traded at the close of the day’s session.
In the last one week, shares of Crispr Therapeutics AG have slipped by -0.32%.
Crispr Therapeutics AG's Key Ratios
Crispr Therapeutics AG has a market cap of $5.01 billion, indicating a price to book ratio of 2.0111 and a price to sales ratio of 253.2571.
In the last 12-months Crispr Therapeutics AG’s revenue was $100.26 million with a gross profit of $-570697000 and an EBITDA of $-538492032. The EBITDA ratio measures Crispr Therapeutics AG's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Crispr Therapeutics AG’s operating margin was -560.23% while its return on assets stood at -14.48% with a return of equity of -25.56%.
In Q1, Crispr Therapeutics AG’s quarterly earnings growth was a positive 0% while revenue growth was a positive 10538.3%.
Crispr Therapeutics AG’s PE and PEG Ratio
- Forward PE
- 23.3645
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-6.81 per share while it has a forward price to earnings multiple of 23.3645 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Crispr Therapeutics AG’s profitability.
Crispr Therapeutics AG stock is trading at a EV to sales ratio of 178.1001 and a EV to EBITDA ratio of -3.4339. Its price to sales ratio in the trailing 12-months stood at 253.2571.
Crispr Therapeutics AG stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.24 billion
- Total Liabilities
- $146.79 million
- Operating Cash Flow
- $117.83 million
- Capital Expenditure
- $3.06 million
- Dividend Payout Ratio
- 0%
Crispr Therapeutics AG ended 2024 with $2.24 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.24 billion while shareholder equity stood at $1.85 billion.
Crispr Therapeutics AG ended 2024 with $0 in deferred long-term liabilities, $146.79 million in other current liabilities, 2452000.00 in common stock, $-899155000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $344.41 million and cash and short-term investments were $344.41 million. The company’s total short-term debt was $15,717,000 while long-term debt stood at $0.
Crispr Therapeutics AG’s total current assets stands at $1.91 billion while long-term investments were $6.32 million and short-term investments were $1.54 billion. Its net receivables were $0 compared to accounts payable of $45.15 million and inventory worth $0.
In 2024, Crispr Therapeutics AG's operating cash flow was $117.83 million while its capital expenditure stood at $3.06 million.
Comparatively, Crispr Therapeutics AG paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $50.37
- 52-Week High
- $86.95
- 52-Week Low
- $38.94
- Analyst Target Price
- $83.42
Crispr Therapeutics AG stock is currently trading at $50.37 per share. It touched a 52-week high of $86.95 and a 52-week low of $86.95. Analysts tracking the stock have a 12-month average target price of $83.42.
Its 50-day moving average was $52.78 and 200-day moving average was $52.16 The short ratio stood at 7.98 indicating a short percent outstanding of 0%.
Around 148.8% of the company’s stock are held by insiders while 6798.4% are held by institutions.
Frequently Asked Questions About Crispr Therapeutics AG
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.